StreetInsider.com News Articles

RenovoRx receives FDA orphan drug designation for oxaliplatin

Thu, 28 May 2026 08:31:28 -0400

RenovoRx Inc. (NASDAQ: RNXT) announced that the U.S. Food and Drug Administration granted orphan drug designation for oxaliplatin in treating pancreatic cancer, according to a company statement.

The designation was issued by the FDA's Office of Orphan Products Development under Section 526 of the Federal Food, Drug, and Cosmetic Act. Oxaliplatin is an approved chemotherapy drug commonly used in cancer treatment.

This marks RenovoRx's third orphan drug designation overall and second for pancreatic cancer. The company previously received designations for intra-arterial gemcitabine delivered via its RenovoCath device for locally advanced pancreatic cancer and bile duct cancer.

The orphan drug designation provides seven years

RenovoRx receives FDA orphan drug designation for oxaliplatin

Thu, 28 May 2026 08:31:28 -0400

RenovoRx Inc. (NASDAQ: RNXT) announced that the U.S. Food and Drug Administration granted orphan drug designation for oxaliplatin in treating pancreatic cancer, according to a company statement.

The orphan drug designation provides seven years

RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer

Thu, 28 May 2026 08:30:00 -0400

Third FDA Orphan Drug Designation Continues to Advance RenovoRx's Therapeutic Oncology Pipeline and Provides Seven Years of Market Exclusivity

MOUNTAIN VIEW, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath^®, a novel, FDA-cleared drug-delivery device, today announced that the U.S. Food and Drug Administration (FDA) recently granted RenovoRx Orphan Drug Designation (ODD) of oxaliplatin for the treatment of pancreatic cancer.

The designation was issued by the FDA’s Office of Orphan Products Development pursuant to Section 526 of the

RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer

Thu, 28 May 2026 08:30:00 -0400

Third FDA Orphan Drug Designation Continues to Advance RenovoRx's Therapeutic Oncology Pipeline and Provides Seven Years of Market Exclusivity

The designation was issued by the FDA’s Office of Orphan Products Development pursuant to Section 526 of the

RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer

Thu, 28 May 2026 08:30:00 -0400

Third FDA Orphan Drug Designation Continues to Advance RenovoRx's Therapeutic Oncology Pipeline and Provides Seven Years of Market Exclusivity

The designation was issued by the FDA’s Office of Orphan Products Development pursuant to Section 526 of the

RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer

Thu, 28 May 2026 08:30:00 -0400

Third FDA Orphan Drug Designation Continues to Advance RenovoRx's Therapeutic Oncology Pipeline and Provides Seven Years of Market Exclusivity

The designation was issued by the FDA’s Office of Orphan Products Development pursuant to Section 526 of the

RenovoRx presents pharmacokinetic data at ASCO meeting

Tue, 26 May 2026 08:32:12 -0400

RenovoRx Inc. (NASDAQ: RNXT) announced that pharmacokinetic data from a sub-study of its Phase III TIGeR-PaC clinical trial was published in connection with the 2026 American Society of Clinical Oncology Annual Meeting held May 29 through June 2 in Chicago.

The sub-study examined the company's TAMP platform for targeted intra-arterial delivery of gemcitabine via its RenovoCath device in locally advanced pancreatic cancer patients. The analysis involved 16 patients across six trial sites and compared intra-arterial gemcitabine administration with intravenous delivery.

Results showed that intra-arterial gemcitabine administration correlated with increased metabolite levels and reduced CA 19-9, a biomarker used to assess chemotherapy response.

RenovoRx presents pharmacokinetic data at ASCO meeting

Tue, 26 May 2026 08:32:12 -0400

Results showed that intra-arterial gemcitabine administration correlated with increased metabolite levels and reduced CA 19-9, a biomarker used to assess chemotherapy response.

RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting

Tue, 26 May 2026 08:30:00 -0400

Sub-Study from Ongoing Phase III TIGeR-PaC Clinical Trial Supports TAMP for Targeted Intra-Arterial Delivery of Gemcitabine, Demonstrating Potential to Increase Local Drug Potency and Reduce Systemic Exposure and Common Side Effects

MOUNTAIN VIEW, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath^®, a patented, FDA-cleared drug-delivery device, today announced that an abstract from a pharmacokinetic (PK) and pharmacodynamic sub-study of its ongoing Phase III TIGeR-PaC clinical trial has been published online in connection with the

RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting

Tue, 26 May 2026 08:30:00 -0400

RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting

Tue, 26 May 2026 08:30:00 -0400

RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting

Tue, 26 May 2026 08:30:00 -0400

Form 4 RenovoRx, Inc. For: May 19 Filed by: VOLL MARK

Thu, 21 May 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260521/26531321.html

Form 4 RenovoRx, Inc. For: May 19 Filed by: VOLL MARK

Thu, 21 May 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260521/26531321.html

RenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20th

Tue, 19 May 2026 08:30:00 -0400

MOUNTAIN VIEW, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced that Chief Executive Officer Shaun Bagai and Chief Financial Officer Mark Voll will participate in the Alliance Global Partners (AGP) Annual Healthcare Company Showcase, hosted by Scott Henry, AGP’s Managing Director and Senior Healthcare Analyst, on May 20, 2026.